Research

The development of a novel high-dose pressurized aerosol dry-powder device (PADD) for the deliverv of pumactant for inhalation therapy


Reference:

Young, P. M., Thompson, J., Woodcock, D., Aydin, M. and Price, R., 2004. The development of a novel high-dose pressurized aerosol dry-powder device (PADD) for the deliverv of pumactant for inhalation therapy. Journal of Aerosol Medicine-Deposition Clearance and Effects in the Lung, 17 Sum (2), pp. 123-128.

Related documents:

This repository does not currently have the full-text of this item.
You may be able to access a copy if URLs are provided below.

Abstract

The performance of a novel dry powder inhaler designed to deliver exceptionally high doses was investigated using pumactant as a model powder. Pumactant (a synthetic lung surfactant consisting of a phospholipid mixture), with a 90th percentile particle size of 2.92mum is highly cohesive, has a high moisture affinity (6.2% w/w at 45% RH), and is predominately amorphous. The device (pressurized aerosol dry-powder delivery [PADD]) utilizes pressurized gas to aerosolize a powder bed from a reservoir and delivers it through a conventional mouthpiece. The influence of loaded dose on dry powder delivery and can pressure on aerosolization efficiency was investigated. Analysis of the delivered dose studies suggested a linear relationship between loaded dose and delivered dose (R-2 = 0.96, for loaded doses of 0-250 mg), with a delivery efficiency of 70%. Analysis of the aerosolization efficiency using a Marple Miller type impactor suggested fine particle fractions (particles with an aerodynamic diameter of

Details

Item Type Articles
CreatorsYoung, P. M., Thompson, J., Woodcock, D., Aydin, M. and Price, R.
DepartmentsFaculty of Science > Pharmacy & Pharmacology
RefereedYes
StatusPublished
ID Code7968
Additional InformationID number: ISI:000222809000003

Export

Actions (login required)

View Item